A similar effort would be welcomed in lower grade gliomas, particularly those with IDH1/IDH2mutation and 1p/19q codeletion, more vulnerable to treatment and therefore representing some kind of ...

Many low-grade gliomas have something known as an IDH-mutation. These mutations can help promote tumor growth. A drug called vorasidenib is an exciting new targeted treatment option for low-grade ...

University of Virginia Health System, Department of Pathology, Division of Neuropathology, Box 800214, Charlottesville, VA 22908-0214, USA (T. D. Bourne). University of Virginia Health System ...

Targeted therapies for gliomas with a marker known as an IDH mutation are a new and exciting option for patients When glioma is completely removed with surgery, observation may be an option.

In data presented at last year’s ASCO congress, vorasidenib was shown to reduce disease progression and death in grade 2 gliomas with IDH mutations compared to placebo and to delay the need for ...

Hence, finding individualized treatment strategies for glioma patients is important to maximize the therapeutic effects. We divided patients into two groups according to IDH mutation status. The ...

However, in 2021, the WHO introduced updated classification criteria for gliomas, and IDH wild-type astrocytomas with EGFR amplification, chromosome 7 acquisition with chromosome 10 deletion and TERT ...

MUSK, a vision-language model, enhances cancer diagnosis by integrating multimodal data, outperforming existing methods in prognosis and treatment predictions.

In this video, Annick Desjardins, MD, professor of neurosurgery, professor of neurology and member of the Duke Cancer Institute, explains how clinicians may treat patients with gliomas of different ...

Concomitant radiotherapy plus temozolomide significantly increased progression-free survival versus radiotherapy alone in IDH ...